Nexcourse BCa Logo

WHEN YOU ARE UNCERTAIN OF HER ER/PR STATUS...GIVE HER ANOTHER CHANCE.

MORE THAN 20% OF WOMEN'S ER/PR STATUS MAY BE MISCLASSIFIED1-4

Inaccurate results may impact treatment decisions, eliminate potentially efficacious therapies or subject patients to therapies known to cause serious adverse events.


Authors Journal Publication Year Marker Discussed Misclassification Rate
Hede K1 JNCI 2008 ER 40%
Allred DC2 JNCCN 2009 ER/PR 20%-30%
Allred DC3 The Oncologist 2008 ER/PR 30%
Hammond ME4 Journal of Clinical Oncology 2010 ER/PR 20%

Table 1. Peer-reviewed literature shows that conventional IHC-based technology can misclassify ER/PR receptor status.


EXPECT ACCURATE AND REPRODUCIBLE RESULTS

NexCourse BCa by AQUA technology is quantitative IHC, providing an accurate and quantitative score for protein expression.

  • More reproducible than routine IHC testing5
  • Minimizes false-negative results by utilizing an objective, quantified score for protein expression5
  • Ideal for confirmatory testing of ER/PR status prior to hormonal and/or chemotherapy
  • Only commercial laboratory to offer AQUA technology

RECONFIRM ER/PR STATUS BEFORE YOU TREAT

Patients identified as ER+ by automated quantitative analysis (AQUA), but ER- by routine IHC, demonstrated similar prognostic outcomes to patients identified as ER+ by both.5


AQUA TECHNOLOGY DEMONSTRATES A HIGHER DEGREE OF CORRELATION

AQUA technology combines the benefits of fluorescent microscopy and automated image analysis with clinically validated antibodies to compute quantitative results.


  1. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst. 2008;100(12):836-844.
  2. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7 Suppl 6:S1-S21;quiz S22-23.
  3. Allred DC. Commentary: hormone receptor testing in breast cancer, a distress signal from Canada. Oncologist. 2008;12(11):1134-1136.
  4. Hammond ME, Hayes DF, Downsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16);2784-2795.
  5. Welsh A, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011;Aug 1:2978-2984.
  6. Gustavson MD. Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology. Presented at the 2009 Annual Meeting of the American Society of Clinical Oncology. May 29-June 2, 2009; Orlando, FL. Abstract #567.


Genoptix® and NexCourse® are registered trademarks of Genoptix, Inc.
AQUA® is a registered trademark of HistoRX, Inc.